Pharmacokinetics, pharmacodynamics and safety profile of the dual orexin receptor antagonist vornorexant/TS‐142 in healthy Japanese participants following single/multiple dosing: Randomized, double‐blind, placebo‐controlled phase‐1 studies
Basic & Clinical Pharmacology & Toxicology · 2023
DOI: 10.1111/bcpt.13930 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, 2023. Verfasst von Daiji Kambe und 8 weiteren Autor:innen. Beteiligte Einrichtung: Development Headquarters, Taisho Pharmaceutical Co., Ltd., Toshima, Tokyo, Japan. Hauptthemen laut MEDLINE: Orexin Receptor Antagonists. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Taisho Pharmaceutical Co., Ltd..
Abstract (Originalsprache)
The pharmacokinetics, pharmacodynamics and safety profile of vornorexant were investigated in healthy Japanese participants in three double‐blind studies: a single ascending dose of 1–30 mg (Study 101; n = 6) and multiple ascending doses of 10–30 mg (Study 102; n = 6). Study 202 consisted of two steps: an open‐label, 20 mg repeated‐dose in non‐elderly individuals (Step 1; n = 12) and a double‐blind, 20 mg repeated‐dose in elderly individuals (Step 2; n = 8/3 for vornorexant/placebo). Vornorexant was rapidly absorbed and eliminated under fasting conditions, with a time to maximum plasma concentration of 0.500–3.00 h (range) and elimination half‐life of 1.32–3.25 h. The area under the plasma concentration‐time curve (AUC) of vornorexant increased proportionally with dose increments. Sleepiness‐related pharmacodynamic outcome changes (Karolinska sleepiness scale, digit symbol substitution test and psychomotor vigilance task) were generally increased with dose increments at 1 and 4 h post‐dose, whereas no consistent dose‐related changes were detected the next morning. Food intake did not affect the maximum observed plasma concentration of vornorexant but increased the AUC 0–inf . Exposure in elderly individuals was generally comparable to that in non‐elderly individuals. Altogether, vornorexant may have a favourable profile for insomnia treatment, including rapid onset of action and minimal next‐day residual effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Development Headquarters, Taisho Pharmaceutical Co., Ltd., Toshima, Tokyo, Japan.
- Research Headquarters, Taisho Pharmaceutical Co., Ltd., Kita, Saitama, Japan.
- Department of Neuropsychiatry, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
- Department of Psychiatry, Nihon University School of Medicine, Itabashi, Tokyo, Japan.
- Tokyoadachi Hospital, Adachi, Tokyo, Japan.
ORCID-Profile: Daiji Kambe
Förderung
- Taisho Pharmaceutical Co., Ltd.
Zitieren
APA
Kambe, D., Hasegawa, S., Imadera, Y., Mano, Y., Matsushita, I., Konno, Y., Ogo, H., Uchimura, N., & Uchiyama, M. (2023). Pharmacokinetics, pharmacodynamics and safety profile of the dual orexin receptor antagonist vornorexant/TS‐142 in healthy Japanese participants following single/multiple dosing: Randomized, double‐blind, placebo‐controlled phase‐1 studies. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.13930
Vancouver
Kambe D, Hasegawa S, Imadera Y, Mano Y, Matsushita I, Konno Y, et al. Pharmacokinetics, pharmacodynamics and safety profile of the dual orexin receptor antagonist vornorexant/TS‐142 in healthy Japanese participants following single/multiple dosing: Randomized, double‐blind, placebo‐controlled phase‐1 studies. Basic & Clinical Pharmacology & Toxicology. 2023. doi:10.1111/bcpt.13930
BibTeX
@article{Kambe2023,
author = {Kambe, Daiji and Hasegawa, Sayaka and Imadera, Yumiko and Mano, Yoko and Matsushita, Isao and Konno, Yoshihiro and Ogo, Hiroki and Uchimura, Naohisa and Uchiyama, Makoto},
title = {Pharmacokinetics, pharmacodynamics and safety profile of the dual orexin receptor antagonist vornorexant/TS‐142 in healthy Japanese participants following single/multiple dosing: Randomized, double‐blind, placebo‐controlled phase‐1 studies},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2023},
doi = {10.1111/bcpt.13930}
}
EUVIMED